The discovery that more than 60% of T-ALL patients harbor mutations in the NOTCH1 gene has generated new perspectives for the treatment of T-ALL through the use of GSIs or small peptides/antibodies that block NOTCH1 signaling and its regulators. This evidence concerns the gene NOTCH1 and acute lymphoblastic leukemia.